Known as the pharmacy of the world, India supplies nearly 20% of global generic volume and more than 60% of global vaccines. The country also boasts the highest number of FDA-compliant plants outside the US. Over the past five years, its pharmaceutical exports have been steadily increasing—from around $20-21 billion in the pre-pandemic period to $30.47 billion in FY25, marking a growth of over 9% year-on-year, according to official data.
More than 60% of its pharma shipments are directed to highly regulated markets, with the US accounting for roughly one-third of exports, followed by Europe and other regulated and emerging markets. Experts attribute the export growth to sustained demand for generics, vaccines, and specialty products, despite pricing pressures in some key segments.
The future also looks promising for India’s pharmaceutical market—the third largest by volume and 11th largest by value (currently $60 billion) globally—with industry estimates indicating a medium-term growth trajectory of 8-10% annually, contingent upon faster regulatory approvals and diversification into complex generics and biosimilars.
Undoubtedly, the potential is immense. However, three key things that are currently bothering the Indian pharma industry are rising compliance costs, tightening global scrutiny, and evolving trade dynamics, all of which are accelerating structural changes, especially for micro, small, and medium enterprises (MSMEs) in this sector. The shifts are also driving the sector toward higher-quality benchmarks and sector-wide consolidation.
The timing of these shifts, though, is not incidental. Industry stakeholders, including the industry body Pharmaceutical Export Promotion Council of India (Pharmexcil) and individual players such as HAB Pharma’s Director Saurabh Agarwal, maintain that the increasing global regulatory scrutiny and a volatile geopolitical environment—ranging from the West Asia conflicts to broader supply chain realignments—are reshaping export priorities for a vital sector that contributes about $30 billion annually to the country’s foreign exchange earnings.
Against this backdrop, three themes have moved sharply into focus: compliance intensity, trade-linked regulatory barriers, and ESG-linked expectations. A senior official at Pharmexcil says that global buyers are increasingly evaluating supplier reliability through the lens of compliance and continuity, not just cost. As markets turn more risk-sensitive, regulatory trust is emerging as a hedge against geopolitical uncertainty, making these shifts immediately relevant for exporters, he says.
